Impact of a novel prognostic model on allogeneic hematopoietic stem cell transplantation outcomes in patients with CMML

JY Zhou, S Wang, HL Yuan, YJ Xu… - American Journal of …, 2023 - Wiley Online Library
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell malignancy,
and allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is the only curable …

[HTML][HTML] Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia

P Pophali, A Matin, AA Mangaonkar, R Carr… - Blood cancer …, 2020 - nature.com
Chronic myelomonocytic leukemia (CMML) is a clonal disorder of aging hematopoietic stem
cells characterized by overlapping features of myeloproliferation and myelodysplasia 1, with …

Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia

K Motohashi, S Fujisawa, N Doki… - Leukemia & …, 2018 - Taylor & Francis
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment
for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT …

[HTML][HTML] Allogeneic hematopoietic cell transplantation for adult chronic myelomonocytic leukemia

HD Liu, KW Ahn, ZH Hu, M Hamadani… - Biology of blood and …, 2017 - Elsevier
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for patients with
chronic myelomonocytic leukemia (CMML); however, few data exist regarding prognostic …

[HTML][HTML] Long-term survival benefit after allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia

N Gagelmann, R Bogdanov, F Stölzel… - … and Cellular Therapy, 2021 - Elsevier
The critical question in the management of chronic myelomonocytic leukemia (CMML) is
which patients may benefit from allogeneic hematopoietic cell transplantation (allo-HCT) …

Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a nationwide …

H Itonaga, M Iwanaga, K Aoki, J Aoki, K Ishiyama… - Leukemia research, 2016 - Elsevier
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a therapeutic option that
may lead to improved outcomes in patients with chronic myelomonocytic leukemia (CMML) …

[HTML][HTML] EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant

A Baranwal, A Mangaonkar, MV Shah… - Bone Marrow …, 2024 - nature.com
Allogeneic stem cell transplant (alloSCT) remains the only potentially curative option for
patients with chronic myelomonocytic leukemia (CMML). Studies evaluating alloSCT …

Role of allogeneic transplantation in chronic myelomonocytic leukemia: an international collaborative analysis

M Robin, LC de Wreede, E Padron… - Blood, The Journal …, 2022 - ashpublications.org
To determine the survival benefit of allogeneic hematopoietic cell transplantation (allo-HCT)
in chronic myelomonocytic leukemias (CMML), we assembled a retrospective cohort of …

[HTML][HTML] Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia

DMB Kerbauy, F Chyou, T Gooley, ML Sorror… - Biology of Blood and …, 2005 - Elsevier
We evaluated the outcomes of allogeneic hematopoietic cell transplantation (HCT) in 43
patients with chronic myelomonocytic leukemia. Patients were classified according to the …

[HTML][HTML] Prognostic impact of donor source on allogeneic hematopoietic stem cell transplantation outcomes in adults with chronic myelomonocytic leukemia: a …

H Itonaga, K Aoki, J Aoki, T Ishikawa, K Ishiyama… - Biology of Blood and …, 2018 - Elsevier
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative therapeutic
option for patients with chronic myelomonocytic leukemia (CMML). We retrospectively …